CompletedPhase 2NCT00084630
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
Studying Dermatofibrosarcoma protuberans
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Scott Schuetze, MD, PhDSWOG Cancer Research Network
- Intervention
- imatinib mesylate(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004
Study locations (1)
- Southwest Oncology Group, San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00084630 on ClinicalTrials.gov